(Q27852414)

13 November 2016

title

KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials (English)

1 reference

PubMed publication ID

13 November 2016

0 references

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

5

Sandro Barni

0 references

Fausto Petrelli

1

Fausto Petrelli

0 references

Mary Cabiddu

3

Mary Cabiddu

0 references

Mara Ghilardi

4

Mara Ghilardi

0 references

Andrea Coinu

2

Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis

Andrea Coinu

0 references

publication date

2013

0 references

1 reference

30

0 references

issue

3

0 references

page(s)

650

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Aggregate data meta-analysis with time-to-event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0650-4

Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study

21 January 2018

1 reference

12 December 2020

The type of K-ras mutation determines prognosis in colorectal cancer

1 reference

12 December 2020

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

1 reference

12 December 2020

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

1 reference

12 December 2020

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

1 reference

12 December 2020

K-ras and p16 aberrations confer poor prognosis in human colorectal cancer

1 reference

12 December 2020